Since many colon cancer [57], pancreatic cancer [58] and lung cancers [59] are associated with KRAS mutations, development of drugs targeting PLK1 kinase could be promising in treatment of these cancers. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.